174 related articles for article (PubMed ID: 9563875)
1. p53 and RB expression predict progression in T1 bladder cancer.
Grossman HB; Liebert M; Antelo M; Dinney CP; Hu SX; Palmer JL; Benedict WF
Clin Cancer Res; 1998 Apr; 4(4):829-34. PubMed ID: 9563875
[TBL] [Abstract][Full Text] [Related]
2. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
3. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
5. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
6. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors.
Cordon-Cardo C; Zhang ZF; Dalbagni G; Drobnjak M; Charytonowicz E; Hu SX; Xu HJ; Reuter VE; Benedict WF
Cancer Res; 1997 Apr; 57(7):1217-21. PubMed ID: 9102201
[TBL] [Abstract][Full Text] [Related]
7. Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer.
Ow K; Delprado W; Fisher R; Barrett J; Yu Y; Jackson P; Russell PJ
J Pathol; 2000 May; 191(1):39-47. PubMed ID: 10767717
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
[TBL] [Abstract][Full Text] [Related]
10. P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer.
Raitanen MP; Tammela TL; Kallioinen M; Isola J
J Urol; 1997 Apr; 157(4):1250-3. PubMed ID: 9120913
[TBL] [Abstract][Full Text] [Related]
11. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma.
Naka T; Toyota N; Kaneko T; Kaibara N
Anticancer Res; 1998; 18(1B):555-64. PubMed ID: 9568177
[TBL] [Abstract][Full Text] [Related]
12. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
13. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53.
Cote RJ; Dunn MD; Chatterjee SJ; Stein JP; Shi SR; Tran QC; Hu SX; Xu HJ; Groshen S; Taylor CR; Skinner DG; Benedict WF
Cancer Res; 1998 Mar; 58(6):1090-4. PubMed ID: 9515785
[TBL] [Abstract][Full Text] [Related]
14. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins.
Chern HD; Becich MJ; Persad RA; Romkes M; Smith P; Collins C; Li YH; Branch RA
J Urol; 1996 Nov; 156(5):1846-9. PubMed ID: 8863629
[TBL] [Abstract][Full Text] [Related]
15. Can p53 staining be used to identify patients with aggressive superficial bladder cancer?
Masters JR; Vani UD; Grigor KM; Griffiths GO; Crook A; Parmar MK; Knowles MA;
J Pathol; 2003 May; 200(1):74-81. PubMed ID: 12692844
[TBL] [Abstract][Full Text] [Related]
16. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications.
Wang X; Jones TD; Maclennan GT; Yang XJ; Lopez-Beltran A; Eble JN; Koch MO; Lin H; Baldridge LA; Tretiakova M; Cheng L
Anticancer Res; 2005; 25(3B):2001-4. PubMed ID: 16158936
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.
Dalbagni G; Parekh DJ; Ben-Porat L; Potenzoni M; Herr HW; Reuter VE
BJU Int; 2007 Feb; 99(2):281-5. PubMed ID: 17155984
[TBL] [Abstract][Full Text] [Related]
19. Molecular changes in superficial bladder cancer.
Vrabie CD; Petrescu A; Waller M
Rom J Morphol Embryol; 2007; 48(2):131-8. PubMed ID: 17641799
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
